How to buy Arvinas stock (ARVN)

Arvinas is a biotechnology business based in the US. Arvinas shares (ARVN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.08 – an increase of 7.01% over the previous week. Arvinas employs 445 staff and has a trailing 12-month revenue of around $161.1 million.

Our top picks for where to buy Arvinas stock

Buy Arvinas stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Arvinas stock price (NASDAQ: ARVN)

Use our graph to track the performance of ARVN stocks over time.

Arvinas shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$19.08
52-week range	$17.37 - $53.08
50-day moving average more info button	$24.54
200-day moving average more info button	$28.59
Wall St. target price	$63.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.79

Is it a good time to buy Arvinas stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arvinas price performance over time

Historical closes compared with the close of $18.73 from 2024-12-24

1 week (2024-12-20)	1.35%
1 month (2024-11-27)	-27.91%
3 months (2024-09-27)	-24.29%
6 months (2024-06-27)	-27.54%

1 year (2023-12-27)	-55.75%
2 years (2022-12-27)	-42.32%
3 years (2021-12-27)	80.78
5 years (2019-12-27)	41.8

Arvinas financials

Revenue TTM	$161.1 million
Gross profit TTM	$131.4 million
Return on assets TTM	-20.07%
Return on equity TTM	-59.16%
Profit margin	-191.56%
Book value	$8.53
Market Capitalization more info button	$1.3 billion

TTM: trailing 12 months

Arvinas share dividends

We're not expecting Arvinas to pay a dividend over the next 12 months.

Arvinas share price volatility

Over the last 12 months, Arvinas's shares have ranged in value from as little as $17.37 up to $53.08. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arvinas's is 1.967. This would suggest that Arvinas's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Arvinas overview

Arvinas, Inc. , a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc. , Genentech, Inc.

Frequently asked questions

null
What percentage of Arvinas is owned by insiders or institutions?
Currently 7.215% of Arvinas shares are held by insiders and 108.732% by institutions. How many people work for Arvinas?
Latest data suggests 445 work at Arvinas. When does the fiscal year end for Arvinas?
Arvinas's fiscal year ends in December. Where is Arvinas based?
Arvinas's address is: 5 Science Park, New Haven, CT, United States, 06511 What is Arvinas's ISIN number?
Arvinas's international securities identification number is: US04335A1051 What is Arvinas's CUSIP number?
Arvinas's Committee on Uniform Securities Identification Procedures number is: 04335A105